Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Anti-aquaporin-4 IgG in Patients Presenting with Unilateral Optic Neuritis: A Cohort Study.
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.
Tobacco smoking and excess mortality in multiple sclerosis: a cohort study.
Erratum to: Genomic Binding Sites and Biological Effects of the Vitamin D-VDR Complex in Multiple Sclerosis.
Novel replication-competent circular DNA molecules from healthy cattle serum and milk and multiple sclerosis-affected human brain tissue.
Atorvastatin: Multiple Sclerosis.
Therapeutic plasma exchange in neuromyelitis optica: A case series.
Notch Signaling and T-Helper Cells in EAE/MS.
Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?
Exercise, brain, and cognition across the life span.
Is the IL-10 Promoter Polymorphism at Position -592 Associated with Immune System-Related Diseases?
Role of early viral infections in development of multiple sclerosis.
Characterization of Axonal Disease in Patients with Multiple Sclerosis Using High-Gradient-Diffusion MR Imaging.
Critical role of activation induced cytidine deaminase in Experimental Autoimmune Encephalomyelitis.
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?
Enhanced Neuroprotective Effects of Combination Therapy with Bone Marrow-Derived Mesenchymal Stem Cells and Ginkgo biloba Extract (EGb761) in a Rat Model of Experimental Autoimmune Encephalomyelitis.
Analysis of the direct injury effector of oligodendroglia cells or myelin sheath in an experimental allergic encephalomyelitis model induced by the MOG35-55 peptide.
Pure sensory Guillain-Barré syndrome: A case report and review of the literature.
Complex assessment in progressive multiple sclerosis: a case report.
Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.
DSM-III disorders from age 11 to age 15 years.
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors.
Chromosomal radiosensitivity in patients with multiple sclerosis.

Pages